Exponent, Inc. — Form 10-Q Summary
Period clarification: Although the request metadata says 2021 Q1, this filing covers the three months ended April 1, 2022, compared with the three months ended April 2, 2021. The filing describes Exponent as an engineering and scientific consulting firm. Figures below are in U.S. dollars.
Financial performance
- Revenue: $128.5 million, up 10.3% year over year. Revenue before reimbursements was $117.9 million, up 8.0%.
- Operating income: $36.7 million, up 52.6%. Operating margin was 28.6% of revenue, compared with 20.7% a year earlier. The filing attributes much of the increase to lower corporate operating expense, including deferred-compensation mark-to-market effects.
- Net income and EPS: Net income was $29.6 million, down 4.0%; diluted EPS was $0.56, versus $0.58. The effective tax rate was 9.7%, compared with negative 2.4%, reflecting a smaller excess tax benefit from stock-based awards.
- Cash flow: Operating cash flow was negative $6.4 million, versus positive $1.3 million. Investing cash flow was negative $2.6 million; financing cash flow was negative $73.4 million. Cash and cash equivalents ended the quarter at $215.1 million, down from $297.7 million at year-end 2021.
- Liquidity and debt: Current assets were $376.7 million and current liabilities $109.1 million. The balance sheet reports no borrowings or debt line item. Management said cash, cash equivalents, short-term investments, and operating cash generation should cover liquidity needs for at least 12 months.
- Margins and operations: Revenue growth reflected increased billable hours and billing rates in Engineering and Other Scientific, as well as higher project activity. Companywide billable hours rose 5% and utilization increased to 77% from 76%.
Changes versus the prior-year quarter
- Engineering and Other Scientific revenue rose 11.8% to $104.6 million; Environmental and Health revenue rose 4.3% to $23.9 million.
- Operating income improved despite higher general and administrative, other operating, and reimbursable expenses. Reimbursable expenses rose 53.7%, primarily with increased project travel and other project costs as pandemic-related restrictions eased.
- Other income shifted to a $3.9 million loss from $6.1 million of income, mainly reflecting a change in deferred-compensation plan asset values. Related compensation expense moved in the opposite direction, partly offsetting the effect on operating results.
- Cash declined primarily alongside share repurchases, dividends, payroll taxes on restricted stock units, and operating cash use. The company repurchased 552,598 shares for $48.6 million at an average $87.87 per share.
Outlook, risks, and notable items
- No numerical revenue or earnings guidance was provided. Management expects compensation costs, other operating expenses, and general and administrative expenses to rise as it hires selectively, adjusts pay, invests in infrastructure, and resumes more office and travel activity.
- Management cited demand from consumer electronics, utilities, chemicals, and life sciences clients, along with rebounding litigation-related work and product-recall activity. It also highlighted continued hiring, cash generation, and shareholder returns as priorities.
- Risks discussed include pandemic-related effects, changes in demand and economic conditions, engagement timing, competition and pricing, employee recruitment and retention, client credit and collectability, litigation and regulatory matters, and foreign-exchange movements. The company does not hedge foreign-currency exposure.
- One client represented 13% of quarterly revenue, compared with 10% in the prior-year quarter. Management reported no material legal proceedings and no material changes to previously disclosed risk factors.
- The board announced a $0.24-per-share dividend payable June 24, 2022, to holders of record June 10, 2022. A further $150 million repurchase authorization was announced in February 2022.
Important facts for investors to verify
- Confirm the reporting period: this is a Q1 2022 filing, not a Q1 2021 filing.
- Assess how much operating-income growth reflects underlying operations versus deferred-compensation accounting effects.
- Monitor cash conversion and working-capital timing, especially annual bonus payments and receivables; net accounts receivable was $147.5 million.
- Track the major-client concentration and whether demand from the cited sectors and litigation-related work continues.
- Review the pace and funding of repurchases and dividends relative to cash generation and management’s stated liquidity needs.